Kurs
-6,26%
Kurs
-6,26%
Open
2,23
High
2,24
Low
1,90
Close
2,10
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Likviditet
16,8 MNOK
Likviditet
16,8 MNOK
Rel. mcap
2,14%
Antal aktier
8 005 414
Likviditet under dagen för detta pressmeddelande
Kalender
| Est. tid* | ||
| 2026-02-25 | 06:30 | Bokslutskommuniké 2025 |
| 2025-11-26 | 07:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-20 | 07:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-28 | 07:00 | Kvartalsrapport 2025-Q1 |
| 2025-05-26 | N/A | Årsstämma |
| 2025-05-23 | N/A | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2025-04-23 | - | Extra Bolagsstämma 2025 |
| 2025-02-26 | - | Bokslutskommuniké 2024 |
| 2024-11-27 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-21 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-21 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2024-05-16 | - | Årsstämma |
| 2024-05-14 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-28 | - | Bokslutskommuniké 2023 |
| 2023-11-15 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-23 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-16 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-12 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2023-05-11 | - | Årsstämma |
| 2023-02-28 | - | Bokslutskommuniké 2022 |
| 2022-11-23 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-24 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-16 | - | Kvartalsrapport 2022-Q1 |
| 2022-05-13 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2022-05-12 | - | Årsstämma |
| 2022-03-31 | - | Bokslutskommuniké 2021 |
| 2021-12-22 | - | Extra Bolagsstämma 2021 |
| 2021-11-17 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-12 | - | Kvartalsrapport 2021-Q1 |
| 2021-05-06 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2021-05-05 | - | Årsstämma |
| 2021-04-21 | - | Bokslutskommuniké 2020 |
| 2020-11-17 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-07-07 | - | Split NYKD 1:5 |
| 2020-07-06 | - | Extra Bolagsstämma |
| 2020-05-12 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-22 | - | Extra Bolagsstämma |
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2025-03-27 13:33:40
Oslo, Norway, March 27, 2025 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced that is has received
notices of termination from Martin Nicklasson, Chair of the Board of Directors
and Elaine Sullivan and Anne Whitaker, members of the Board of Directors.
Further, Nykode has received notices of termination from Michael Engsig, Chief
Executive Officer, Agnete Fredriksen, Chief Scientific Officer & Co-founder and
Harald Gurvin, Chief Financial Officer. They will continue to support the
company until further notice.
The Board will as soon as possible call for an Extraordinary General Meeting to
elect a new Board.
This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 the Norwegian Securities Trading Act. This stock exchange
announcement was published by Harald Gurvin, CFO at Nykode Therapeutics ASA, on
March 27, 2025 at 13:33 CET.